Hyperbaric oxygen treatment augments the efficacy of cilazapril and simvastatin regimens in an experimental nephrotic syndrome model

Clinical and Experimental Nephrology

Volumn 12, Issue 2, 2008, Pages 110-118

  Sonmez, Alper ^a   Yilmaz, Mahmut Ilker ^a,b   Korkmaz, Ahmet ^a   Topal, Turgut ^a   Caglar, Kayser ^a   Kaya, Ayper ^a   Eyileten, Tayfun ^a   Yenicesu, Mujdat ^a   Oguz, Yusuf ^a   Basal, Seref ^a   Ipcioglu, Osman Metin ^a   Vural, Abdulgaffar ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

ACE inhibitor; Hyperbaric oxygen; Proteinuria; Sprague Dawley rat; Statin

Indexed keywords

CILAZAPRIL; DOXORUBICIN; GLUTATHIONE PEROXIDASE; SIMVASTATIN; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; HISTOPATHOLOGY; HYPERBARIC OXYGEN; KIDNEY BIOPSY; MALE; NEPHROTIC SYNDROME; NONHUMAN; OXIDATIVE STRESS; PROTEIN CARBONYLATION; PROTEINURIA; RAT; SURVIVAL RATE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIOXIDANTS; CILAZAPRIL; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; DOXORUBICIN; GLUTATHIONE PEROXIDASE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERBARIC OXYGENATION; KIDNEY; MALE; NEPHROTIC SYNDROME; OXIDATIVE STRESS; PROTEIN CARBONYLATION; PROTEINURIA; RATS; RATS, SPRAGUE-DAWLEY; SIMVASTATIN; SUPEROXIDE DISMUTASE;

EID: 40849116251     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-007-0017-2     Document Type: Article

References (39)

1. Sies H. Oxidative stress oxidants, antioxidants. Exp Physiol. 1997;82:291-5.
2. Giordano FJ. Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest. 2005;115(3):500-8.
3. Haugen E, Nath KA. The involvement of oxidative stress in the progression of renal injury. Blood Purif. 1999;17(2-3):58-65.
4. Modlinger PS, Wilcox CS, Aslam S. Nitric oxide, oxidative stress, and progression of chronic renal failure. Semin Nephrol. 2004;24(4):354-65.
5. Okuda S, Oh Y, Tsuruda H, Onoyama K, Fujimi S, Fujishima M. Adriamycin-induced nephropathy as a model of chronic progressive glomerular disease. Kidney Int. 1986;29(2):502-10.
6. Powis G. Free radical formation by antitumor quinones. Free Radic Biol Med. 1989;6(1):63-101.
7. Raats CJ, Bakker MA, van den Born J, Berden JH. Hydroxyl radicals depolymerize glomerular heparan sulfate in vitro and in experimental nephrotic syndrome. J Biol Chem. 1997;272(42):26734-41.
8. Barbey MM, Fels LM, Soose M, Poelstra K, Gwinner W, Bakker W, et al. Adriamycin affects glomerular renal function: evidence for the involvement of oxygen radicals. Free Radic Res Commun. 1989;7(3-6):195-203.
9. Yilmaz MI, Korkmaz A, Kaya A, Sonmez A, Caglar K, Topal T, et al. Hyperbaric oxygen treatment augments the efficacy of a losartan regime in an experimental nephrotic syndrome model. Nephron Exp Nephrol. 2006;104(1):e15-22.
10. Kusumoto Y, Takebayashi S, Taguchi T, Harada T, Naito S. Long-term prognosis and prognostic indices of IgA nephropathy in juvenile and in adult Japanese. Clin Nephrol. 1987;28(3):118-24.
11. Bader H, Meyer DS. The size of the juxtaglomerular apparatus in diabetic glomerulosclerosis and its correlation with arteriolosclerosis and arterial hypertension: a morphometric light microscopic study on human renal biopsies. Clin Nephrol. 1977;8(1):308-11.
12. Wehrmann M, Bohle A, Held H, Schumm G, Kendziorra H, Pressler H. Long-term prognosis of focal sclerosing glomerulonephritis. An analysis of 250 cases with particular regard to tubulointerstitial changes. Clin Nephrol. 1990;33(3):115-22.
13. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin-phenol reagent. J Biol Chem. 1951;193:265-75.
14. Levine RL, Garland D, Oliver CN, Amici A, Climent I, Lenz AG, et al. Determination of carbonyl content in oxidatively modified proteins. In: Packer L, Glazer AN, editors. Methods in enzymology, oxygen radicals in biological systems. California: Academic; 1990;186:464-78.
15. Sun Y, Oberley LW, Ying L. A simple method for clinical assay of superoxide dismutase. Clin Chem. 1988;34:497-500.
16. Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterisation of erythrocyte glutathione peroxidase. J Lab Clin Med. 1967;70:158-69.
17. Foster LH, Sumar S. Selenium in health and disease: a review. Crit Rev Food Sci Nutr. 1997; 37:211-28.
18. Avissar N, Ornt DB, Yagil Y, Horowitz S, Watkins RH, Kerl EA, et al. Human kidney proximal tubules are the main source of plasma glutathione peroxidase. Am J Physiol. 1994;266:C367-75.
19. Whitin JC, Tham DM, Bhamre S, Ornt DB, Scandling JD, Tune BM, et al. Plasma glutathione peroxidase and its relationship to renal proximal tubule function. Mol Genet Metab. 1998;65:238-45.
20. Locatelli F, Canaud B, Eckardt KU. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant. 2003;18:1272.
21. Klahr S. Oxygen radicals and renal diseases. Miner Electrolyte Metab. 1997;23:140.
22. Nangaku M. The heat is on: an expanding role for hypoxia-inducible factors in kidney transplantation. J Am Soc Nephrol. 2007;18(1):13-5.
23. Eckardt KU, Bernhardt WM, Weidemann A, Warnecke C, Rosenberger C, Wiesener MS, et al. Role of hypoxia in the pathogenesis of renal disease. Kidney Int. 2005;Suppl (99):S46-51.
24. Palm F. Intrarenal oxygen in diabetes and a possible link to diabetic nephropathy. Clin Exp Pharmacol Physiol. 2006;33(10):997-1001.
25. Yilmaz MI, Saglam M, Caglar K, Cakir E, Sonmez A, Ozgurtas T, et al. The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis. 2006;47(1):42-50.
26. Vural A, Yilmaz MI, Caglar K, Aydin A, Sonmez A, Eyileten T, et al. Assessment of oxidative stress in the early posttransplant period: comparison of cyclosporine A and tacrolimus-based regimens. Am J Nephrol. 2005;25(3):250-55.
27. Washio M, Nanishi F, Okuda S, Onoyama K, Fujishima M. Alpha tocopherol improves focal glomerulosclerosis in rats with adriamycin-induced progressive renal failure. Nephron. 1994;68(3):347-52.
28. Okasora T, Takikawa T, Utsunomiya Y, Senoh I, Hayashibara H, Shiraki K, et al. Suppressive effect of superoxide dismutase on adriamycin nephropathy. Nephron. 1992;60(2):199-203.
29. Saran R, Novak JE, Desai A, Abdulhayoglu E, Warren JS, Bustami R, et al. Impact of vitamin E on plasma asymmetric dimethylarginine (ADMA) in chronic kidney disease (CKD): a pilot study. Nephrol Dial Transplant. 2003;18(11):2415-20.
30. Oter S, Edremitlioglu M, Korkmaz A, et al: Effects of hyperbaric oxygen treatment on liver functions, oxidative status and histology in septic rats. Intensive Care Med. 2005;31(9):1262-68.
31. Ozden TA, Uzun H, Bohloli M, Coskun O, Kilic D, Kisa U, et al. The effects of hyperbaric oxygen treatment on oxidant and antioxidants levels during liver regeneration in rats. Tohoku J Exp Med. 2004;203(4):253-65.
32. Li Y, Zhou C, Calvert JW, Colohan AR, Zhang JH. Multiple effects of hyperbaric oxygen on the expression of HIF-1 alpha and apoptotic genes in a global ischemia-hypotension rat model. Exp Neurol. 2005;191(1):198-210.
33. Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int. 2005;67(3):799-812.
34. Fogo A, Yoshida Y, Glick AD, Homma T, Ichikawa I. Serial micropuncture analysis of glomerular function in two rat models of glomerular sclerosis. J Clin Invest. 1988;82(1):322-30.
35. Lapinski R, Perico N, Remuzzi A, Sangalli F, Benigni A, Remuzzi G et al. Angiotensin II modulates glomerular capillary permselectivity in rat isolated perfused kidney. J Am Soc Nephrol. 1996;7(5):653-60.
36. Fenster BE, Tsao PS, Rockson SG. Endothelial dysfunction: clinical strategies for treating oxidant stress. Am Heart J. 2003;146(2):218-26.
37. Yilmaz MI, Baykal Y, Kilic M, Sonmez A, Bulucu F, Aydin A, et al. Effects of statins on oxidative stress. Biol Trace Elem Res. 2004;98(2):119-27.
38. Haas MJ, Horani MH, Parseghian SA, Mooradian AD. Statins prevent dextrose-induced endothelial barrier dysfunction, possibly through inhibition of superoxide formation. Diabetes. 2006;55(2):474-79.
39. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol. 2006;17(7): 2006-16.